2010
DOI: 10.1128/cvi.00264-10
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Recombinant adenovirus or DNA vaccines encoding herpes simplex virus type 1 (HSV-1) glycoprotein D (gD) genetically fused to human papillomavirus type 16 (HPV-16) oncoproteins (E5, E6, and E7) induce antigenspecific CD8؉ T-cell responses and confer preventive resistance to transplantable murine tumor cells (TC-1 cells). In the present report, we characterized some previously uncovered aspects concerning the induction of CD8 ؉ T-cell responses and the therapeutic anticancer effects achieved in C57BL/6 mice immu… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
39
0
10

Year Published

2011
2011
2019
2019

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 35 publications
(51 citation statements)
references
References 42 publications
2
39
0
10
Order By: Relevance
“…cells and it seems that using the older mice is better maybe for having more developed immune systems (20,21). Despite the reduction in tumor size in the group that received peptide alone, it was not statistically significant by using 50 µg/kg of the peptide (12).…”
Section: Groupmentioning
confidence: 95%
“…cells and it seems that using the older mice is better maybe for having more developed immune systems (20,21). Despite the reduction in tumor size in the group that received peptide alone, it was not statistically significant by using 50 µg/kg of the peptide (12).…”
Section: Groupmentioning
confidence: 95%
“…Our group has developed different DNA vaccine vectors encoding the HPV-16 oncoproteins genetically fused with the herpes simplex virus type 1 (HSV-1) gD protein (6,7). The im administration of such DNA vaccines has shown enhanced preventive and therapeutic anti-tumor effects in mice implanted with tumor cells expressing the HPV-16 E7 and E6 oncoproteins.…”
Section: Introductionmentioning
confidence: 99%
“…The im administration of such DNA vaccines has shown enhanced preventive and therapeutic anti-tumor effects in mice implanted with tumor cells expressing the HPV-16 E7 and E6 oncoproteins. Recently, we reported the development of a DNA vaccine vector (pgD-E7E6E5) encoding three HPV-16 oncoproteins (E7, E6, and E5) with enhanced anticancer effects relative to the previously reported vaccines based on one (E7) or two (E7 and E6) oncoproteins (7). This newly developed vaccine conferred up to 70% therapeutic anti-tumor protection in mice with established tumor implants after the im administration of three vaccine doses (100 µg DNA/dose).…”
Section: Introductionmentioning
confidence: 99%
“…DNA vaccines that encoded the HPV16 E5, E6 and E7 proteins genetically fused to HSV-1 glycoprotein D have already shown promising results in the control of cervical cancer in the preclinical mouse model (Diniz et al, 2010).…”
mentioning
confidence: 99%